|
|||||
|
Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter |
Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
AXNX | Noblett Karen | Chief Medical Officer | Jan 31 | Option Exercise | 0.00 | 27,500 | 0 | 45,716 | Feb 02 05:59 PM |
AXNX | Noblett Karen | Chief Medical Officer | Jan 31 | Sale | 67.74 | 11,288 | 764,603 | 34,428 | Feb 02 05:59 PM |
AXNX | Noblett Karen | Chief Medical Officer | Jan 08 | Sale | 69.00 | 15,999 | 1,103,961 | 18,216 | Jan 10 08:00 PM |
AXNX | Noblett Karen | Chief Medical Officer | Dec 26 | Sale | 63.00 | 949 | 59,787 | 41,266 | Dec 28 07:17 PM |
AXNX | Noblett Karen | Chief Medical Officer | Dec 28 | Sale | 63.28 | 7,051 | 446,177 | 34,215 | Dec 28 07:17 PM |
AXNX | Noblett Karen | Chief Medical Officer | Jan 31 | Option Exercise | 0.00 | 10,250 | 0 | 46,849 | Feb 02 08:06 PM |
AXNX | Noblett Karen | Chief Medical Officer | Jan 31 | Sale | 61.15 | 3,703 | 226,437 | 43,146 | Feb 02 08:06 PM |
AXNX | Noblett Karen | Chief Medical Officer | Feb 01 | Sale | 60.93 | 931 | 56,727 | 42,215 | Feb 02 08:06 PM |
AXNX | Noblett Karen | Chief Medical Officer | Sep 12 | Option Exercise | 19.19 | 32,483 | 623,335 | 64,082 | Sep 20 08:23 PM |
AXNX | Noblett Karen | Chief Medical Officer | Sep 12 | Sale | 78.16 | 32,483 | 2,538,800 | 31,599 | Sep 20 08:23 PM |
AXNX | Noblett Karen | Chief Medical Officer | Sep 07 | Sale | 71.53 | 10,454 | 747,794 | 31,599 | Sep 09 08:06 PM |
AXNX | Noblett Karen | Chief Medical Officer | Mar 18 | Sale | 57.23 | 13,531 | 774,359 | 42,053 | Mar 22 08:52 PM |
AXNX | Noblett Karen | Chief Medical Officer | Feb 03 | Option Exercise | 0.00 | 19,463 | 0 | 62,266 | Feb 03 09:32 PM |
AXNX | Noblett Karen | Chief Medical Officer | Feb 03 | Sale | 48.25 | 6,682 | 322,421 | 55,584 | Feb 03 09:32 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite